Cyclopentenone prostaglandins - New allies in the war on inflammation

Nature Medicine

Volumn 6, Issue 2, 2000, Pages 137-138

  Willoughby, Derek A ^a   Moore, Adrian R ^a   Colville Nash, Paul R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPENTENONE; PROSTAGLANDIN;

ANTIINFLAMMATORY ACTIVITY; CATALYSIS; CHEMICAL REACTION; COMPLEX FORMATION; ELECTROLYTE BALANCE; ENZYME ACTIVITY; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN MODIFICATION; SHORT SURVEY; TARGET CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; ENZYME INHIBITORS; I-KAPPA B KINASE; INFLAMMATION; PROSTAGLANDIN ANTAGONISTS; PROSTAGLANDINS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 0033950209     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/72224     Document Type: Article

References (14)

1. Rossi, A. et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase (IKK). Nature 403, 103-108 (2000).
2. Gilroy, D.W. et al. Inducible cyclooxygenase may have anti-inflammatory properties. Nature Med. 5, 698-701 (1999).
3. Willoughby, D.W., Moore, A.R. & Colville-Nash, P.R. COX-1., COX-2., COX-3? An hypothesis on the future treatment of chronic inflammatory disease. Lancet (in the press).
4. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature New Biol. 231, 232-235 (1971).
5. DiRosa, M., Giroud, J.P. & Willoughby, D.A. Studies on the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine. J. Pathol. 104, 15-29 (1971).
6. Xie, W., Chipman, J.G., Robertson, D.L., Erikson, R.L. & Simmons, D.L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA. 88, 2692-2696 (1991).
7. Seibert, K. et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and in pain. Proc. Natl. Acad. Sci. USA. 91, 12013-12017 (1994).
8. Willoughby, D.A. Effects of PGF2a and PGE1 on vascular permeability. J. Pathol. Bacteriol. 96, 381-387 (1968).
9. Capasso, F. et al. Pharmacological mediators of various immunological and non-immunological inflammatory reactions produced in the pleural cavity. Agents Actions 5, 528-533 (1975).
10. Schmassmann, A. et al. Effects of inhibition of prostaglandin endoperoxide synthase 2 in gastric intestinal models in rats. Br. J. Pharmacol. 123, 795-805 (1998).
11. Appleton, I., Tomlinson, A., Mitchell, J.A. & Willoughby, D.A. Distribution of cyclooxygenase isoforms in murine chronic granulomatous inflammation. Implications for future anti-inflammatory therapy. J. Pathol. 176, 413-420 (1995).
12. Simmons, D.L., Botting, R.M., Robertson, P.M., Madsen, M.L. & Vane, J.R. Induction of an acetaminofen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs. Proc. Natl. Acad. Sci. USA. 96, 3275-3280 (1999).
13. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J. & Glass, C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79-82 (1998).
14. Wiesenberg, I. et al. Specific activation of the nuclear receptors PPARgamma and RORA by the antidiabetic thiazolidenedione BRL 49563 and the anti-arthritic thiazolidenedione CGP 52608. Mol. Pharmacol. 53, 1131-1138 (1998).